Litigation Details for AbbVie Inc. v. Hetero USA, Inc. (D. Del. 2024)
✉ Email this page to a colleague
AbbVie Inc. v. Hetero USA, Inc. (D. Del. 2024)
Docket | ⤷ Sign Up | Date Filed | 2024-08-08 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
Jury Demand | None | Referred To | |
Patents | 8,962,629; RE47,221 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in AbbVie Inc. v. Hetero USA, Inc.
Biologic Drugs cited in AbbVie Inc. v. Hetero USA, Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .
Details for AbbVie Inc. v. Hetero USA, Inc. (D. Del. 2024)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2024-08-08 | 4 | Patent/Trademark Report to Commissioner of Patents | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE47,221 E; 8,962,629 B2; 11,976,077… 8 August 2024 1:24-cv-00924 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |